Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology
Elsemiek E C Engwerda, Evertine J Abbink, Cees J Tack, Bastiaan E de Galan, Elsemiek E C Engwerda, Evertine J Abbink, Cees J Tack, Bastiaan E de Galan
Abstract
Objective: Insulin administered by jet injectors is dispensed over a larger subcutaneous area than insulin injected with a syringe, which may facilitate a more rapid absorption. This study compared the pharmacologic profile of administration of insulin aspart by jet injection to that by conventional insulin pen.
Research design and methods: Euglycemic glucose clamp tests were performed in 18 healthy volunteers after subcutaneous administration of 0.2 units/kg body wt of aspart, either administered by jet injection or by conventional pen, using a randomized, double-blind, double-dummy, cross over study design. Pharmacodynamic and pharmacokinetic profiles were derived from the glucose infusion rate (GIR) needed to maintain euglycemia and from plasma insulin levels, respectively.
Results: The time to maximal GIR was significantly shorter when insulin was injected with the jet injector compared with conventional pen administration (51 ± 3 vs. 105 ± 11 min, P < 0.0001). The time to peak insulin concentration was similarly reduced (31 ± 3 vs. 64 ± 6 min, P < 0.0001) and peak insulin concentrations were increased (108 ± 13 vs. 79 ± 7 mU/L, P = 0.01) when insulin was injected by jet injection compared with conventional pen injection. Jet injector insulin administration reduced the time to 50% glucose disposal by ∼40 min (P < 0.0001). There were no differences in maximal GIR, total insulin absorption, or total insulin action between the two devices.
Conclusions: Administration of insulin aspart by jet injection enhances insulin absorption and reduces the duration of glucose-lowering action. This profile resembles more closely the pattern of endogenous insulin secretion and may help to achieve better meal insulin coverage and correction of postprandial glucose excursions.
Figures
References
- Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 2006;5:543–548
- Weller C, Linder M. Jet injection of insulin vs the syringe-and-needle method. JAMA 1966;195:844–847
- Taylor R, Home PD, Alberti KG. Plasma free insulin profiles after administration of insulin by jet and conventional syringe injection. Diabetes Care 1981;4:377–379
- Pehling GB, Gerich JE. Comparison of plasma insulin profiles after subcutaneous administration of insulin by jet spray and conventional needle injection in patients with insulin-dependent diabetes mellitus. Mayo Clin Proc 1984;59:751–754
- Hallé JP, Lambert J, Lindmayer I, et al. . Twice-daily mixed regular and NPH insulin injections with new jet injector versus conventional syringes: pharmacokinetics of insulin absorption. Diabetes Care 1986;9:279–282
- Malone JI, Lowitt S, Grove NP, Shah SC. Comparison of insulin levels after injection by jet stream and disposable insulin syringe. Diabetes Care 1986;9:637–640
- Kerum G, Profozić V, Granić M, Skrabalo Z. Blood glucose and free insulin levels after the administration of insulin by conventional syringe or jet injector in insulin treated type 2 diabetics. Horm Metab Res 1987;19:422–425
- Lucas A, Ribas L, Salinas I, Audí L, Sanmartí A, Foz M. Insulin levels after injection by jet stream and disposable syringe. Diabetes Care 1988;11:298–299
- Sarno MJ, Bell J, Edelman SV. Pharmacokinetics and glucodynamics of rapid-, short-, and intermediate-acting insulins: comparison of jet injection to needle syringe. Diabetes Technol Ther 2002;4:863–866
- Mudaliar SR, Lindberg FA, Joyce M, et al. . Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501–1506
- Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396–402
- Heise T, Weyer C, Serwas A, et al. . Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998;21:800–803
- DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214–E223
- Luijf YM, DeVries JH. Dosing accuracy of insulin pens versus conventional syringes and vials. Diabetes Technol Ther 2010;12(Suppl. 1):S73–S77
- Thurman JE. Insulin pen injection devices for management of patients with type 2 diabetes: considerations based on an endocrinologist’s practical experience in the United States. Endocr Pract 2007;13:672–678
- Heinemann L, Anderson JH, Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther 2004;6:698–718
- Abumrad NN, Rabin D, Diamond MP, Lacy WW. Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism 1981;30:936–940
- Abbink EJ, van der Wal PS, Sweep CG, Smits P, Tack CJ. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation. Diabetes Metab Res Rev 2004;20:466–471
- Abbink EJ, Walker AJ, van der Sluijs HA, Tack CJ, Smits P. No role of calcium- and ATP-dependent potassium channels in insulin-induced vasodilation in humans in vivo. Diabetes Metab Res Rev 2002;18:143–148
- Asakura T, Seino H, Nakano R, et al. . A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol Ther 2009;11:657–661
- Bremseth DL, Pass F. Delivery of insulin by jet injection: recent observations. Diabetes Technol Ther 2001;3:225–232
- Borg R, Kuenen JC, Carstensen B, et al. ; ADAG Study Group. HbA1(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia 2011;54:69–72
Source: PubMed